Nuveen’s Metagenomi Therapeutics MGX Stock Holding History

Nuveen’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-63,248	Closed	-$86K	–	3433
2025 Q1	$86K	Hold	63,248	–	–	﹤0.01%	3228
2024 Q4	$228K	Buy	+63,248	New	+$153K	﹤0.01%	3184

Other funds holding MGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVGI

Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen's MGX Position: Q2 2025 in Review

Nuveen sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 63,248 shares — an estimated $86K sold.

Nuveen first reported a position in MGX in Q4 2024 and held it in 2 quarters. The position peaked at $228K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

Nuveen reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
Nuveen sold 63,248 Metagenomi Therapeutics shares in Q2 2025, an estimated $86K.
Nuveen first reported a position in Metagenomi Therapeutics in Q4 2024 and held it in 2 quarters.
Nuveen's Metagenomi Therapeutics position peaked at $228K in Q4 2024.
69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.